236 related articles for article (PubMed ID: 32305507)
1. Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid.
Ren G; Qin Z; Yang N; Chen H; Fu K; Lu C; Lu Y; Li N; Zhang Y; Chen X; Zhao D
Chem Biol Interact; 2020 Jun; 324():109097. PubMed ID: 32305507
[TBL] [Abstract][Full Text] [Related]
2. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
[TBL] [Abstract][Full Text] [Related]
3. Preclinical assessment of drug-drug interaction of fb-PMT, a novel anti-cancer thyrointegrin αvβ3 antagonist.
Fujioka K; Fekry MI; Rumsey JM; Steiner T; Thompson D; Mousa SA
Clin Transl Sci; 2023 Jun; 16(6):987-1001. PubMed ID: 36967488
[TBL] [Abstract][Full Text] [Related]
4. Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K).
Kikuchi R; Lao Y; Bow DA; Chiou WJ; Andracki ME; Carr RA; Voorman RL; De Morais SM
J Pharm Sci; 2013 Dec; 102(12):4426-32. PubMed ID: 24122511
[TBL] [Abstract][Full Text] [Related]
5. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.
Misaka S; Knop J; Singer K; Hoier E; Keiser M; Müller F; Glaeser H; König J; Fromm MF
Mol Pharm; 2016 Feb; 13(2):512-9. PubMed ID: 26702643
[TBL] [Abstract][Full Text] [Related]
6. Transporter-mediated Natural Product-Drug Interactions.
Bi Y; Wang X; Ding H; He F; Han L; Zhang Y
Planta Med; 2023 Feb; 89(2):119-133. PubMed ID: 35304735
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of
Parvez MM; Shin HJ; Jung JA; Shin JG
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223391
[No Abstract] [Full Text] [Related]
8. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
[TBL] [Abstract][Full Text] [Related]
9. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
10. Interactions Between Meropenem and Renal Drug Transporters.
Dong J; Liu Y; Li L; Ding Y; Qian J; Jiao Z
Curr Drug Metab; 2022 Aug; 23(5):423-431. PubMed ID: 35490314
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor.
Taniguchi T; Ashizawa N; Matsumoto K; Saito R; Motoki K; Sakai M; Chikamatsu N; Hagihara C; Hashiba M; Iwanaga T
J Pharmacol Exp Ther; 2019 Oct; 371(1):162-170. PubMed ID: 31371478
[TBL] [Abstract][Full Text] [Related]
12. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
Ebner T; Ishiguro N; Taub ME
J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin.
Stopfer P; Giessmann T; Hohl K; Sharma A; Ishiguro N; Taub ME; Zimdahl-Gelling H; Gansser D; Wein M; Ebner T; Müller F
Clin Pharmacol Ther; 2016 Sep; 100(3):259-67. PubMed ID: 27256812
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of SLC drug transporter activities by environmental bisphenols.
Bruyere A; Hubert C; Le Vee M; Chedik L; Sayyed K; Stieger B; Denizot C; Parmentier Y; Fardel O
Toxicol In Vitro; 2017 Apr; 40():34-44. PubMed ID: 27989701
[TBL] [Abstract][Full Text] [Related]
15. Renal Drug Transporters and Drug Interactions.
Ivanyuk A; Livio F; Biollaz J; Buclin T
Clin Pharmacokinet; 2017 Aug; 56(8):825-892. PubMed ID: 28210973
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein.
Knop J; Misaka S; Singer K; Hoier E; Müller F; Glaeser H; König J; Fromm MF
PLoS One; 2015; 10(10):e0139370. PubMed ID: 26426900
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
[TBL] [Abstract][Full Text] [Related]
18. Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition.
Hanna I; Alexander N; Crouthamel MH; Davis J; Natrillo A; Tran P; Vapurcuyan A; Zhu B
Xenobiotica; 2018 Mar; 48(3):300-313. PubMed ID: 28281384
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of hepatic uptake transporters by flavonoids.
Mandery K; Balk B; Bujok K; Schmidt I; Fromm MF; Glaeser H
Eur J Pharm Sci; 2012 May; 46(1-2):79-85. PubMed ID: 22394605
[TBL] [Abstract][Full Text] [Related]
20. Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters.
Shoaf SE; Bricmont P; Repella Gordon J
Clin Transl Sci; 2021 Jul; 14(4):1535-1542. PubMed ID: 33742787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
